How to access Empaveli from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient with paroxysmal nocturnal hemoglobinuria (PNH), particularly one who remains anaemic or transfusion-dependent despite prior C5-inhibitor therapy, may be evaluated by their treating haematologist for Empaveli (pegcetacoplan). Empaveli is FDA-approved in the United States and developed by Apellis Pharmaceuticals (partnered with Sobi outside the US). It is a PEGylated C3 complement inhibitor, acting upstream of C5, which allows it to address both intravascular and extravascular haemolysis in PNH. Empaveli is rarely locally registered outside the US and EU, and for UAE patients the named-patient import pathway via MoHAP is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
Ask about Empaveli in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Empaveli is administered as a twice-weekly subcutaneous infusion using an infusion pump (commercial mini-pump, delivered over 30 minutes). Because Empaveli inhibits C3 rather than C5, it carries the same class-level warning about encapsulated-organism infections; vaccination (meningococcus, pneumococcus, H. influenzae type B) ahead of therapy is a gating step. Your treating haematologist confirms PNH diagnosis (flow cytometry), prior therapy history, vaccination completion, and the monitoring plan per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Empaveli legally importable into the UAE?
Yes, through the MoHAP / Drugs Controller General of the UAE (DCGI) personal-use and hospital-sponsored named-patient import frameworks. The route permits a registered medical practitioner to request import of a medicine not locally registered when the medicine is approved by a recognised reference authority (FDA qualifies), no clinically equivalent registered option fits, and chain of custody is documented.
For ultra-rare PNH therapy, UAE tertiary haematology centres in Mumbai, Delhi, Bangalore, Chennai, Hyderabad, and Kolkata are experienced with named-patient imports, and diaspora-supported care is a common pattern.
How the pathway works, step by step
- Consultation with your treating haematologist. PNH flow cytometry confirmation, prior therapy history, and clinical rationale.
- Pre-treatment vaccination. Meningococcal, pneumococcal, and Hib vaccinations per labeling, typically at least 2 weeks before first dose or with appropriate prophylaxis.
- MoHAP application. The physician or hospital files the personal-use / named-patient application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner for Empaveli and the infusion pump / administration supplies.
- Cold-chain shipment. Empaveli ships at 2-8°C with continuous temperature monitoring and chain-of-custody documentation end to end.
- Arrival, training, and ongoing twice-weekly infusion. The haematology unit or home-care partner supports training on the infusion pump; ongoing administration is typically at home after training.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming PNH, diagnostic evidence (flow cytometry), prior therapies, and Empaveli as the indicated treatment
- Verification of their UAE medical registration (NMC)
- Patient identifier and address for the import record
- Vaccination documentation
- Planned twice-weekly infusion schedule and training plan
Reserve Meds provides a physician documentation kit that bundles the templates UAE customs and MoHAP reviewers expect to see for complement inhibitors, plus the infusion-pump training note.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. International cold-chain logistics, customs clearance, MoHAP documentation handling, and coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Ongoing supplies ship on a rolling basis.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: PNH is an ultra-rare condition with long treatment horizons; UAE diaspora families frequently co-fund care across generations and cities. Our case lead is set up to include every designated family member on coordination and document flow.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Empaveli specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP / customs review.
- Logistics. Cold-chain, temperature-monitored, internationally tracked shipment of drug and infusion-pump supplies.
- Dedicated case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP personal-use / named-patient framework with appropriate documentation.
Why Empaveli rather than a C5 inhibitor? Empaveli inhibits C3 upstream, addressing both intravascular and extravascular haemolysis. For patients who remain anaemic on C5 inhibition, this upstream mechanism can be clinically relevant. Your haematologist will decide.
Can the family abroad pay directly? Yes. Diaspora-supported invoicing is common for ultra-rare-disease care.
Will insurance cover this? Cash-pay is the default. Some UAE insurers and diaspora policies consider ultra-rare-disease named-patient imports on escalated review; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Empaveli coordination in the UAE, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Empaveli in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Empaveli for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Empaveli in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Empaveli. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Empaveli in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Empaveli to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Empaveli to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Empaveli in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Empaveli in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.